189 related articles for article (PubMed ID: 38173044)
21. Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma.
Liu Z; Cheng X; Pang B; Wang S; Liu B; Cao C; Qian R; Liang W; Zhu Y; Li P; Gao Y
Int Immunopharmacol; 2022 Mar; 104():108399. PubMed ID: 35008004
[TBL] [Abstract][Full Text] [Related]
22. An N6-methyladenosine regulation- and mRNAsi-related prognostic index reveals the distinct immune microenvironment and immunotherapy responses in lower-grade glioma.
Tang G; Peng J; Huo L; Yin W
BMC Bioinformatics; 2023 Jun; 24(1):225. PubMed ID: 37264314
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive Analysis of Ferroptosis Regulators with Regard to PD-L1 and Immune Infiltration in Low-Grade Glioma.
Luan Y; Chen Y; Wang Y; Shu M
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629061
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the prognostic significance and potential mechanisms of lncRNAs associated with m6A methylation in papillary thyroid carcinoma.
Huang Y; Li X; Chen W; He Y; Wu S; Li X; Hou B; Wang S; He Y; Jiang H; Lun Y; Zhang J
Int Immunopharmacol; 2021 Dec; 101(Pt B):108286. PubMed ID: 34735975
[TBL] [Abstract][Full Text] [Related]
25. MrGPS: an m6A-related gene pair signature to predict the prognosis and immunological impact of glioma patients.
Zhang N; Yang F; Zhao P; Jin N; Wu H; Liu T; Geng Q; Yang X; Cheng L
Brief Bioinform; 2023 Nov; 25(1):. PubMed ID: 38171932
[TBL] [Abstract][Full Text] [Related]
26. Potential role of m6A RNA methylation regulators in osteosarcoma and its clinical prognostic value.
Liu H; Qin G; Ji Y; Wang X; Bao H; Guan X; Wei A; Cai Z
J Orthop Surg Res; 2021 May; 16(1):294. PubMed ID: 33952279
[TBL] [Abstract][Full Text] [Related]
27. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
28. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
[TBL] [Abstract][Full Text] [Related]
29. N7-methylguanosin regulators-mediated methylation modification patterns and characterization of the immune microenvironment in lower-grade glioma.
Maimaiti A; Feng Z; Liu Y; Turhon M; Xie Z; Baihetiyaer Y; Wang X; Kasimu M; Jiang L; Wang Y; Wang Z; Pei Y
Eur J Med Res; 2023 Mar; 28(1):144. PubMed ID: 36998056
[TBL] [Abstract][Full Text] [Related]
30. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.
Guo Y; Bai Y; Wang L; Xu Z; Wang X; Wang W
Medicine (Baltimore); 2022 Jul; 101(26):e29818. PubMed ID: 35777046
[TBL] [Abstract][Full Text] [Related]
31. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
[TBL] [Abstract][Full Text] [Related]
32. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive analysis of m
Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
Front Immunol; 2022; 13():955848. PubMed ID: 36203569
[TBL] [Abstract][Full Text] [Related]
34. Effects of N6-Methyladenosine Regulators on LAG3 and Immune Infiltrates in Lung Adenocarcinoma.
Wang N; Xu Y; Jin L; Wang X; Wu S; Wang Y; Zhao J; Zhou F; Ge H
Dis Markers; 2022; 2022():1829528. PubMed ID: 36051357
[TBL] [Abstract][Full Text] [Related]
35. N6-methyladenosine regulators are potential prognostic biomarkers for multiple myeloma.
Wang J; Zuo Y; Lv C; Zhou M; Wan Y
IUBMB Life; 2023 Feb; 75(2):137-148. PubMed ID: 36177774
[TBL] [Abstract][Full Text] [Related]
36. A Whole Exon Screening-Based Score Model Predicts Prognosis and Immune Checkpoint Inhibitor Therapy Effects in Low-Grade Glioma.
Luo C; Wang S; Shan W; Liao W; Zhang S; Wang Y; Xin Q; Yang T; Hu S; Xie W; Xu N; Zhang Y
Front Immunol; 2022; 13():909189. PubMed ID: 35769464
[TBL] [Abstract][Full Text] [Related]
37. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.
Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X
J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565
[TBL] [Abstract][Full Text] [Related]
38. Integrated machine learning methods identify FNDC3B as a potential prognostic biomarker and correlated with immune infiltrates in glioma.
Wang X; Huang Y; Li S; Zhang H
Front Immunol; 2022; 13():1027154. PubMed ID: 36275754
[TBL] [Abstract][Full Text] [Related]
39. N6-methyladenosine methylation regulator FTO promotes oxidative stress and induces cell apoptosis in ovarian cancer.
Wu J; Wang X; Li X
Epigenomics; 2022 Dec; 14(23):1509-1522. PubMed ID: 36815224
[TBL] [Abstract][Full Text] [Related]
40. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
